AMENDMENT NUMBER ONE TO LICENSE AGREEMENTLicense Agreement • August 13th, 2018 • Gritstone Oncology, Inc. • Biological products, (no disgnostic substances)
This Amendment Number One to License Agreement (“Amendment No. 1”) is made by and between (a) Gritstone Oncology, Inc., a Delaware corporation having a place of business at 5858 Horton Street, Suite 210, Emeryville, California 94608, U.S.A. (“Gritstone”), on the one hand, and (b) Protiva Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Arbutus Biopharma Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“ABUS” and together with Protiva, “Arbutus”), on the other hand. Gritstone, Protiva, and ABUS may each be referred to herein as a “Party” and collectively as the “Parties.”
